Concepedia

NANETS Treatment Guidelines

Matthew H. Kulke, Lowell Anthony, David Bushnell, Wouter W. de Herder, Stanley J. Goldsmith, David S. Klimstra, Stephen J. Marx, Janice L. Pasieka, Rodney F. Pommier, James C. Yao,

Pancreas · 2010 · 569 citations · 121 references

DOIFull text

Open access

Concepts

Abstract

Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classification and management of patients with these tumor subtypes. We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies.

References

121

A 5‐decade analysis of 13,715 carcinoid tumors

Irvin M. Modlin, Kevin D. Lye, Mark Kidd · Cancer · 2003 · 2.7K citations

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system

Guido Rindi, G. Klöppel, H. Alhman et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2006 · 1.6K citations · Full text

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

Michael Gabriel, Clemens Decristoforo, Dorota Kendler et al. · Journal of Nuclear Medicine · 2007 · 1K citations · Full text